Novartis AG ADR (NVS)vsTeck Resources Ltd Class B (TECK)
NVS
Novartis AG ADR
$146.03
+0.44%
HEALTHCARE · Cap: $277.42B
TECK
Teck Resources Ltd Class B
$60.76
-2.02%
BASIC MATERIALS · Cap: $29.77B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 356% more annual revenue ($56.58B vs $12.41B). NVS leads profitability with a 23.9% profit margin vs 14.9%. NVS appears more attractively valued with a PEG of 2.59. TECK earns a higher WallStSmart Score of 73/100 (B).
NVS
Buy51
out of 100
Grade: C-
TECK
Strong Buy73
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-51.8%
Fair Value
$110.12
Current Price
$146.03
$35.91 premium
Margin of Safety
+9.1%
Fair Value
$66.42
Current Price
$60.76
$5.66 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 35 in profit
Strong operational efficiency at 30.5%
Keeps 24 of every $100 in revenue as profit
Generating 2.9B in free cash flow
Strong operational efficiency at 39.8%
Revenue surging 72.2% year-over-year
Earnings expanding 128.8% YoY
Reasonable price relative to book value
Areas to Watch
Grey zone — moderate risk
Expensive relative to growth rate
Revenue declined 0.7%
Earnings declined 9.3%
Grey zone — moderate risk
ROE of 5.9% — below average capital efficiency
Expensive relative to growth rate
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 23.9% and operating margin at 30.5%.
Bull Case : TECK
The strongest argument for TECK centers on Operating Margin, Revenue Growth, EPS Growth. Revenue growth of 72.2% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are Altman Z-Score, PEG Ratio, Revenue Growth.
Bear Case : TECK
The primary concerns for TECK are Altman Z-Score, Return on Equity, PEG Ratio.
Key Dynamics to Monitor
NVS profiles as a declining stock while TECK is a growth play — different risk/reward profiles.
TECK carries more volatility with a beta of 1.57 — expect wider price swings.
TECK is growing revenue faster at 72.2% — sustainability is the question.
NVS generates stronger free cash flow (2.9B), providing more financial flexibility.
Bottom Line
TECK scores higher overall (73/100 vs 51/100) and 72.2% revenue growth. Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →Teck Resources Ltd Class B
BASIC MATERIALS · OTHER INDUSTRIAL METALS & MINING · USA
Teck Resources Limited is dedicated to exploring, acquiring, developing and producing natural resources in Asia, Europe and North America. The company is headquartered in Vancouver, Canada.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?